Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: MAIA )

2.200 +0.400 (+22.22%)
Official Closing Price Updated: 8:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 157,509
Open 1.820
Bid (Size) 2.000 (5)
Ask (Size) 2.210 (9)
Prev. Close 1.800
Today's Range 1.750 - 2.200
52wk Range 1.420 - 5.220
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MAIA Biotechnology Announces Share Repurchase Program
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire

Performance

YTD
-37.85%
-37.85%
1 Month
+18.92%
+18.92%
3 Month
+1.38%
+1.38%
6 Month
-38.38%
-38.38%
1 Year
-35.86%
-35.86%

More News

Read More
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
7 Up-and-Coming Stocks to Buy for the Next Decade
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
TRACON Pharmaceuticals And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
MAIA Biotechnology, Inc. Announces Closing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Down 50 Points; US Home Price Index Rises In February
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Aaron's Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
JOANN And 3 Other Stocks Under $4 Insiders Are Aggressively Buying
Via Benzinga
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at AACR Annual Meeting 2023
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.